Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech
April 07 2015 - 9:10AM
Business Wire
Regulatory News:
At today’s Annual General Shareholders' Meeting (AGM) of
Sartorius Stedim Biotech S.A. in Aubagne, France, shareholders
approved the Board of Directors’ proposals by a large majority.
The AGM thus passed the resolution to pay dividends of €1.30 net
per share for fiscal 2014, up from €1.20 a year earlier. The total
profit distributed will therefore rise from €18.4 million to €20.0
million.
The AGM elected new non-executive members to the Board of
Directors: Anne Marie Graffin, Managing Director of SMAG Consulting
SARL, and Susan Dexter, Principal Consultant of the Latham Biopharm
Group. As a result, the number of Board members has increased from
eight to ten. In addition, Oscar-Werner Reif’s term on the Board
was renewed following his initial appointment in 2009. As Executive
Vice President, he also manages the Group’s global Research &
Development unit.
This press release contains statements about the future
development of the Sartorius Stedim Biotech Group. We cannot
guarantee that the content of these statements will actually apply
because these statements are based upon assumptions and estimates
that harbor certain risks and uncertainties.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech (Paris:DIM) is a leading provider of
cutting-edge products and services for the development, quality
assurance and production processes of the biopharmaceutical
industry. Its integrated solutions covering fermentation, cell
cultivation, filtration, purification, fluid management and lab
technologies are supporting the biopharmaceutical industry around
the world to develop and produce drugs safely, timely and
economically. Sartorius Stedim Biotech focuses on single-use
technologies and value-added services to meet the rapidly changing
technology requirements of the industry it serves. Strongly rooted
in the scientific community and closely allied with customers and
technology partners, the company is dedicated to its philosophy of
“turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is
listed on the Eurolist of Euronext Paris. With its own
manufacturing and R&D sites in Europe, North America and Asia
and a global network of sales companies, Sartorius Stedim Biotech
has a worldwide presence. Its key manufacturing and R&D site is
in Germany. The company employs approx. 3,700 people, and in 2014
earned sales revenue of 683.5 million euros.
Petra Kirchhoff; Vice President of Corporate
CommunicationsSartorius Corporate Administration GmbHPhone:
+49(0)551.308.1686;Fax: +49(0)551.308.3410E-mail:
petra.kirchhoff@sartorius.com;www.sartorius-stedim.com
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Nov 2024 to Dec 2024
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Dec 2023 to Dec 2024
